Personalised mRNA cancer vaccines have advanced into clinical reality after demonstrating positive outcomes in late-stage trials for melanoma patients. Researchers combined individually tailored mRNA vaccines with existing immunotherapy drugs, showing that this combination approach can reduce recurrence and death rates in skin cancer.
The vaccine works by training a patient's immune system to recognise and attack cancer-specific mutations. Scientists sequence each tumour, identify its unique genetic changes, then manufacture an mRNA vaccine encoding those mutations. When administered, the vaccine prompts the body to generate immune cells that hunt down cancer cells bearing those exact genetic signatures.
This personalised approach addresses a fundamental limitation of standard cancer treatments. While chemotherapy and radiation damage cancer broadly, they harm healthy tissue too. Immunotherapy drugs like checkpoint inhibitors work by releasing the immune system's brakes, but they lack specific targets. By combining a tailored mRNA vaccine with checkpoint inhibitors, researchers amplify the immune response specifically against the cancer.
The trial results come from BioNTech and Merck, published in leading medical journals. Melanoma patients who received the personalised BNT121 vaccine alongside Merck's Keytruda immunotherapy showed improved disease-free survival compared to those receiving Keytruda alone. The results suggest the approach extends survival and reduces the likelihood of cancer returning.
Researchers now plan to test personalised mRNA vaccines against colorectal cancer, ovarian cancer, and other tumour types. The personalised manufacturing process remains expensive and time-intensive, requiring three to four weeks of production per patient. Scale-up challenges and manufacturing costs will determine whether this approach becomes accessible beyond wealthy healthcare systems.
Limitations persist. The vaccine requires tumour material for sequencing, making it impractical for some cancers detected late. Long-term safety data remains limited, and the approach works best paired with existing immunotherapy drugs rather than as standalone